Nice action by a Pharmaceutical company

| No Comments
From Wired magazine:
A Drug to Eradicate Diarrhea
Napo Pharmaceuticals is poised to launch the first Third World blockbuster drug.

It sounds counterintuitive -- drugs marketed to poor people don't typically lead to big profits. But Lisa Conte, Napo's founder and CEO, hopes not only to bring an affordable diarrhea medication to millions of people in developing nations, but also to reshape the pharmaceutical industry.

The current development model for drug companies is fizzling, she said. More and more prospective blockbuster medications are failing in the final stages of development, and companies will have to consider selling at a lower price to larger numbers of less affluent customers.

"The pharmaceutical industry of the future needs to include emerging and developing economies," Conte said at the Biotechnology Industry Organization annual meeting last month in Philadelphia. "We're not going to be able to enjoy the pricing we have in the past."
And the business model in question:
Last Thursday, Napo announced a deal with Glenmark in India to develop and commercialize Crofelemer as a pediatric and acute infectious diarrhea treatment. Napo signed a similar deal on June 15 with Asiapharm in China.

The deals bypass the typical pharmaceutical approach: Target rich people and charge a high price. Under that model, drugs typically are available in the developing world about 15 years after they've been introduced in premium-price markets like North America and Europe, when patents have expired or companies can afford to distribute excess drugs at a loss.

This is one of the first times a drug will be introduced in poorer markets.
And the drug in question:
Crofelemer comes from the South American tree croton lechleri, which is known by locals as dragon's blood because a machete to its bark brings a blood-like ooze. The extract can treat diarrhea, but too much of it can also make the patient sick. Shaman researchers isolated a molecule from the extract that can be given in larger doses.

Indigenous people "led us to a situation where we could make and improve a pharmaceutical product as far as safety and efficacy and get it back to the population that provided the information," Conte said.

Crofelemer has an advantage over other treatments such as Immodium. While drugs like Immodium are absorbed into the blood and distributed throughout the body, Crofelemer acts locally only in the gut, preventing interactions with other drugs the patient might be taking.

Also, "anti-motility" drugs like Immodium slow down flow of material through the intestine. While this stops diarrhea, it also allows whatever toxin is causing the diarrhea to linger in the body longer, giving it an extra opportunity to infect its host. That's why children, whose immune systems are not fully developed, as well as adult patients with immune problems like AIDS, can't take anti-motility medications.

Crofelemer instead stops the flow of excess water, which makes it possibly the first effective treatment for children and AIDS patients.
Interesting... The article doesn't mention if Napo is going through FDA approval for use in the USA. This is a big hurdle and costs a lot of money. It is not a bad business model to market volume especially if the cost of entry is not that high. Dehydration is a major killer -- many diseases: AIDS, Cholera etc... cause massive problems and with no clean source of water, the patient is open to all sorts of secondary problems with other diseases and parasites. This will be interesting to watch.

Leave a comment

October 2022

Sun Mon Tue Wed Thu Fri Sat
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31          

Environment and Climate
AccuWeather
Cliff Mass Weather Blog
Climate Depot
Ice Age Now
ICECAP
Jennifer Marohasy
Solar Cycle 24
Space Weather
Watts Up With That?


Science and Medicine
Junk Science
Life in the Fast Lane
Luboš Motl
Medgadget
Next Big Future
PhysOrg.com


Geek Stuff
Ars Technica
Boing Boing
Don Lancaster's Guru's Lair
Evil Mad Scientist Laboratories
FAIL Blog
Hack a Day
Kevin Kelly - Cool Tools
Neatorama
Slashdot: News for nerds
The Register
The Daily WTF


Comics
Achewood
The Argyle Sweater
Chip Bok
Broadside Cartoons
Day by Day
Dilbert
Medium Large
Michael Ramirez
Prickly City
Tundra
User Friendly
Vexarr
What The Duck
Wondermark
xkcd


NO WAI! WTF?¿?¿
Awkward Family Photos
Cake Wrecks
Not Always Right
Sober in a Nightclub
You Drive What?


Business and Economics
The Austrian Economists
Carpe Diem
Coyote Blog


Photography and Art
Digital Photography Review
DIYPhotography
James Gurney
Joe McNally's Blog
PetaPixel
photo.net
Shorpy
Strobist
The Online Photographer


Blogrolling
A Western Heart
AMCGLTD.COM
American Digest
The AnarchAngel
Anti-Idiotarian Rottweiler
Babalu Blog
Belmont Club
Bayou Renaissance Man
Classical Values
Cobb
Cold Fury
David Limbaugh
Defense Technology
Doug Ross @ Journal
Grouchy Old Cripple
Instapundit
iowahawk
Irons in the Fire
James Lileks
Lowering the Bar
Maggie's Farm
Marginal Revolution
Michael J. Totten
Mostly Cajun
Neanderpundit
neo-neocon
Power Line
ProfessorBainbridge.com
Questions and Observations
Rachel Lucas
Roger L. Simon
Samizdata.net
Sense of Events
Sound Politics
The Strata-Sphere
The Smallest Minority
The Volokh Conspiracy
Tim Blair
Velociworld
Weasel Zippers
WILLisms.com
Wizbang


Gone but not Forgotten...
A Coyote at the Dog Show
Bad Eagle
Steven DenBeste
democrats give conservatives indigestion
Allah
BigPictureSmallOffice
Cox and Forkum
The Diplomad
Priorities & Frivolities
Gut Rumbles
Mean Mr. Mustard 2.0
MegaPundit
Masamune
Neptunus Lex
Other Side of Kim
Publicola
Ramblings' Journal
Sgt. Stryker
shining full plate and a good broadsword
A Physicist's Perspective
The Daily Demarche
Wayne's Online Newsletter

About this Entry

This page contains a single entry by DaveH published on July 11, 2005 5:57 PM.

While we are on the subject of GR8 was the previous entry in this blog.

Two Quotes is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Monthly Archives

Pages

OpenID accepted here Learn more about OpenID
Powered by Movable Type 5.2.9